Abstract
Cardiomyopathies are categorized as extrinsic, being caused by external factors, such as hypertension, ischemia, inflammation, valvular dysfunction, or as intrinsic, which correspond to myocardial diseases without identifiable external causes. These so called primary cardiomyopathies can be categorized in four main forms: hypertrophic, dilated, restrictive, and arrhythmogenic right ventricular cardiomyopathy. Cardiomyopathies are diagnosed by clinical expression, echocardiography, electrocardiography, non-invasive imaging, and sometimes by cardiac catheterization to rule out external causes as ischemia. The two main forms of primary cardiomyopathies are the hypertrophic and dilated cardiomyopathies. Most of hypertrophic cardiomyopathy and 20-50% of dilated cardiomyopathy are familial showing a wide genetic and phenotypic heterogeneity. This review presents the current knowledge on the causative genes, molecular mechanisms and the genotype–phenotype relations of hypertrophic and dilated cardiomyopathies.
Keywords: Cardiomyopathy, hypertrophy, dilatation, genetics, mutation
Current Pharmaceutical Biotechnology
Title:Genetics of Hypertrophic and Dilated Cardiomyopathy
Volume: 13 Issue: 13
Author(s): Felix W. Friedrich and Lucie Carrier
Affiliation:
Keywords: Cardiomyopathy, hypertrophy, dilatation, genetics, mutation
Abstract: Cardiomyopathies are categorized as extrinsic, being caused by external factors, such as hypertension, ischemia, inflammation, valvular dysfunction, or as intrinsic, which correspond to myocardial diseases without identifiable external causes. These so called primary cardiomyopathies can be categorized in four main forms: hypertrophic, dilated, restrictive, and arrhythmogenic right ventricular cardiomyopathy. Cardiomyopathies are diagnosed by clinical expression, echocardiography, electrocardiography, non-invasive imaging, and sometimes by cardiac catheterization to rule out external causes as ischemia. The two main forms of primary cardiomyopathies are the hypertrophic and dilated cardiomyopathies. Most of hypertrophic cardiomyopathy and 20-50% of dilated cardiomyopathy are familial showing a wide genetic and phenotypic heterogeneity. This review presents the current knowledge on the causative genes, molecular mechanisms and the genotype–phenotype relations of hypertrophic and dilated cardiomyopathies.
Export Options
About this article
Cite this article as:
W. Friedrich Felix and Carrier Lucie, Genetics of Hypertrophic and Dilated Cardiomyopathy, Current Pharmaceutical Biotechnology 2012; 13 (13) . https://dx.doi.org/10.2174/1389201011208062467
DOI https://dx.doi.org/10.2174/1389201011208062467 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immunopathological Aspects of Mycoplasma pneumoniae Infection
Current Pediatric Reviews A Comprehensive Literature Search: Drugs as Possible Triggers of Takotsubo Cardiomyopathy
Current Clinical Pharmacology Usefulness of 5 Minutes <sup>123</sup>I-mIBG Scan in Parkinson’s Disease and Heart Failure
Current Radiopharmaceuticals Impact of Pulmonary Vascular Resistances in Heart Transplantation for Congenital Heart Disease
Current Cardiology Reviews Bicycloheptylamine-Doxorubicin Conjugate: Synthesis and Anticancer Activities in σ2 Receptor-Expressing Cell Lines
Medicinal Chemistry Postoperative Care of the Transplanted Patient
Current Cardiology Reviews Immunomodulatory Activity of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy The Role of microRNA-126 in Vascular Homeostasis
Current Vascular Pharmacology Pharmacological Modulations of the Renin-Angiotensin-Aldosterone System in Human Congestive Heart Failure: Effects on Peripheral Vascular Endothelial Function
Current Vascular Pharmacology Heme Oxygenase: A Target Gene for Anti-Diabetic and Obesity
Current Pharmaceutical Design The Future of Induced Pluripotent Stem Cells for Cardiac Therapy and Drug Development
Current Pharmaceutical Design Updates on HCN Channels in the Heart: Function, Dysfunction and Pharmacology
Current Drug Targets Research Advancements in Porcine Derived Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Polymorphism Gln27Glu of β2 Adrenergic Receptors in Patients with Ischaemic Cardiomyopathy
Current Vascular Pharmacology Cardiovascular Effects of Neuregulin-1/ErbB Signaling: Role in Vascular Signaling and Angiogenesis
Current Pharmaceutical Design Anesthetic Pharmacology and Perioperative Considerations for Heart Transplantation
Current Clinical Pharmacology New Developments in Targeted Analysis of Protein Posttranslational Modifications
Current Proteomics Melatonin Causes Gene Expression in Aged Animals to Respond to Inflammatory Stimuli in a Manner Differing from that of Young Animals
Current Aging Science Patent Selections
Recent Patents on Cardiovascular Drug Discovery Study of Prolactin Permeation Through the Pericardium and Its Bioavailability
Protein & Peptide Letters